UFP Technologies, Inc. is an American multinational developer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products. UFP Technologies manufactures a wide range of single-use medical devices, components, and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| UFPT | UFP TECHNOLOGIES INC | 2026-05-22 14:59:42 | 229.25 | 4 | 1.78 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UFPT | 0000914156 | UFP TECHNOLOGIES INC | US9026731029 | 549300RJ8LY41HS70C91 | 042314970 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 100 HALE STREET | NEWBURYPORT | MA | 01950 | UNITED STATES | US | 978-352-2200 | 100 HALE STREET, NEWBURYPORT, MA, 01950 | 100 HALE STREET, NEWBURYPORT, MA, 01950 | — | — | 1963 | R. Jeffrey Bailly | 3,293 | — | 1,814,993,392 | 7,766,498 | 7,736,939 | UFP Technologies, Inc. is an American multinational developer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products. UFP Technologies manufactures a wide range of single-use medical devices, components, and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. | 2026-05-21 16:57:08 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 1,814,993,392 | -100,829,202 | -5.263 | 7,713,300 | 32,995 | 0.4296 |
| 2024 | 1,915,822,594 | 531,929,770 | 38.4372 | 7,680,305 | 38,422 | 0.5028 |
| 2023 | 1,383,892,824 | 830,967,498 | 150.2857 | 7,641,883 | 31,832 | 0.4183 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Christopher P. Litterio | Senior Vice President, General Counsel, Secretary | 2025 | 385,000 | — | 550,000 | 221,438 | 32,450 | 1,188,888 |
| Ronald J. Lataille | Senior Vice President, Treasurer, Chief Financial Officer | 2025 | 485,000 | — | 1,650,000 | 350,954 | 34,326 | 2,520,280 |
| R. Jeffrey Bailly | Chief Executive Officer | 2025 | 789,000 | — | 5,377,499 | 1,260,934 | 221,007 | 7,648,440 |
| Mitchell C. Rock | President | 2025 | 525,000 | — | 1,650,000 | 388,704 | 34,338 | 2,598,042 |
| Jason Holt | Senior Vice President | 2025 | 352,000 | — | 439,999 | 159,160 | 29,591 | 980,750 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 4,846 |
| 2024 | 4,146 |
| 2023 | 3,093 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 602,797,000 | 504,421,000 | 400,072,000 |
| Cost Of Revenue | 432,387,000 | 357,728,000 | 287,847,000 |
| Gross Profit | 170,410,000 | 146,693,000 | 112,225,000 |
| Research And Development Expenses | 8,600,000 | 10,400,000 | 7,200,000 |
| General And Administrative Expenses | 77,439,000 | 62,218,000 | 50,889,000 |
| Operating Expenses | 78,072,000 | 65,796,000 | 54,561,000 |
| Operating Income | 92,338,000 | 80,897,000 | 57,664,000 |
| Net Income | 68,313,000 | 58,981,000 | 44,924,000 |
| Earnings Per Share Basic | 8.87 | 7.69 | 5.89 |
| Earnings Per Share Diluted | 8.75 | 7.58 | 5.83 |
| Weighted Average Shares Outstanding Basic | 7,705,000 | 7,668,000 | 7,624,000 |
| Weighted Average Shares Outstanding Diluted | 7,804,000 | 7,785,000 | 7,701,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 20,301,000 | 13,450,000 | 5,263,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 82,914,000 | 84,677,000 | 64,449,000 |
| Inventories | 86,856,000 | 87,536,000 | 70,191,000 |
| Non Trade Receivables | 5,310,000 | 4,979,000 | 1,297,000 |
| Other Assets Current | 5,620,000 | 4,303,000 | 3,433,000 |
| Total Assets Current | 201,001,000 | 194,945,000 | 144,633,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 79,109,000 | 70,564,000 | 62,137,000 |
| Other Assets Non Current | 3,444,000 | 447,000 | 469,000 |
| Total Assets Non Current | 454,076,000 | 434,050,000 | 259,503,000 |
| Total Assets | 655,077,000 | 628,995,000 | 404,136,000 |
| Accounts Payable | 24,289,000 | 24,269,000 | 22,286,000 |
| Deferred Revenue | 4,240,000 | 4,667,000 | 6,616,000 |
| Short Term Debt | 12,500,000 | 12,500,000 | 4,000,000 |
| Other Liabilities Current | 28,796,000 | 30,410,000 | 22,085,000 |
| Total Liabilities Current | 74,862,000 | 76,295,000 | 58,209,000 |
| Long Term Debt | 135,455,000 | 189,375,000 | 32,000,000 |
| Other Liabilities Non Current | 3,525,000 | 11,144,000 | 15,181,000 |
| Total Liabilities Non Current | 156,338,000 | 209,940,000 | 59,836,000 |
| Total Liabilities | 231,200,000 | 286,235,000 | 118,045,000 |
| Common Stock | 77,000 | 77,000 | 76,000 |
| Retained Earnings | 374,814,000 | 306,501,000 | 247,520,000 |
| Accumulated Other Comprehensive Income | 3,708,000 | -4,165,000 | 268,000 |
| Total Shareholders Equity | 423,877,000 | 342,760,000 | 286,091,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 9,400,000 | 8,000,000 | 7,000,000 |
| Share Based Compensation Expense | 8,854,000 | 6,842,000 | 4,641,000 |
| Other Non Cash Income Expense | -38,000 | -106,000 | -145,000 |
| Change In Accounts Receivable | -5,337,000 | -1,217,000 | 9,124,000 |
| Change In Inventories | -3,901,000 | 4,686,000 | 16,565,000 |
| Change In Non Trade Receivables | 548,000 | 3,404,000 | 2,982,000 |
| Change In Other Assets | 5,996,000 | -629,000 | -1,557,000 |
| Change In Accounts Payable | -1,090,000 | -1,142,000 | 1,553,000 |
| Change In Other Liabilities | -5,741,000 | -6,541,000 | 408,000 |
| Cash From Operating Activities | 91,905,000 | 66,593,000 | 41,334,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | — | 9,656,000 | 10,490,000 |
| Acquisition Of Business | 14,722,000 | 197,477,000 | 0 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -27,597,000 | -210,164,000 | -10,488,000 |
| Tax Withholding For Share Based Compensation | 4,117,000 | 4,954,000 | 2,641,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 8,854,000 | 6,842,000 | 64,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 0 | 125,000,000 | 0 |
| Repayment Of Long Term Debt | 12,500,000 | 35,125,000 | 4,000,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -58,156,000 | 152,393,000 | -30,024,000 |
| Change In Cash | 6,851,000 | 8,187,000 | 812,000 |
| Cash At End Of Period | 20,301,000 | 13,450,000 | 5,263,000 |
| Income Taxes Paid | 3,558,000 | 12,829,000 | 10,568,000 |
| Interest Paid | 9,855,000 | 7,893,000 | 3,537,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 8.87 | 7.69 | 5.89 |
| Price To Earnings Ratio | 25.0316 | 31.7958 | 29.2088 |
| Earnings Growth Rate | 15.3446 | 30.5603 | 6.7029 |
| Price Earnings To Growth Ratio | 1.6313 | 1.0404 | 4.3576 |
| Book Value Per Share | 55.0132 | 44.7001 | 37.5251 |
| Price To Book Ratio | 4.0359 | 5.47 | 4.5847 |
| Ebitda | 91,075,000 | 87,871,000 | 66,137,000 |
| Enterprise Value | 1,838,395,150 | 2,063,327,680 | 1,342,369,960 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.3491 | 0.589 | 0.1258 |
| Capital Expenditures | 17,945,000 | 16,427,000 | 11,065,000 |
| Free Cash Flow | 73,960,000 | 50,166,000 | 30,269,000 |
| Return On Equity | 0.1612 | 0.1721 | 0.157 |
| One Year Beta | 0.8434 | 1.7315 | 0.9252 |
| Three Year Beta | 1.0623 | 0.9008 | 0.7718 |
| Five Year Beta | 0.8923 | 0.8569 | 0.7805 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| CROTEAU DANIEL C | Director | 2026-05-12 | 2,864 | D | 855 |
| CROTEAU DANIEL C | Director | 2026-05-08 | 2,864 | A | 3,719 |
| CROTEAU DANIEL C | Director | 2026-05-08 | 2,864 | D | 0 |
| OBERDORF THOMAS | Director | 2026-03-11 | 2,864 | A | 12,417 |
| OBERDORF THOMAS | Director | 2026-03-11 | 2,864 | D | 0 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Liontrust Investment Partners LLP | 2026-03-31 | 339,381 | 1,753 | 193.6001 |
| JANUS HENDERSON GROUP PLC | 2026-03-31 | 3,764,009 | 19,436 | 193.6617 |
| CIM, LLC | 2026-03-31 | 384,296 | 1,985 | 193.6 |
| Amundi | 2026-03-31 | 338,026 | 1,746 | 193.6002 |
| EverSource Wealth Advisors, LLC | 2026-03-31 | 3,291 | 17 | 193.5882 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| BUFFALO FUNDS | 2026-03-31 | Institutional Class | BUIOX | 5,320 | 1,029,952 | 1.6802 |
| BUFFALO FUNDS | 2026-03-31 | Investor Class | BUFOX | 5,320 | 1,029,952 | 1.6802 |
| AQR Funds | 2026-03-31 | Class R6 | QSMRX | 853 | 165,140.8 | 0.099 |
| AQR Funds | 2026-03-31 | Class N | ASMNX | 853 | 165,140.8 | 0.099 |
| AQR Funds | 2026-03-31 | Class I | ASMOX | 853 | 165,140.8 | 0.099 |